Background: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant. Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 are effective in preventing UTI in people with SCI compared to placebo.
(Continued from previous page) Discussion: If these probiotics are shown to be effective in preventing UTI and MRO colonisation, they would be a very attractive alternative for UTI prophylaxis and for combating the increasing rate of antibiotic resistance after SCI. UTIs have a high societal cost and current prevention strategies do not work. People with neurogenic bladder are at significant risk from UTI with approximately two [2] UTI episodes per year on average for persons with SCI [1] . One of the major clinical challenges for SCI patients and clinicians is that when patients get a UTI, simple oral antibiotics frequently are ineffective due to the high numbers of multi-resistant-organism [s] [MROs] within SCI populations [about 40-50 % of SCI people] [1, 2] . This greatly amplifies the health, societal and economic consequences of disease and can even lead to life threatening clinical problems that can spread if not controlled through hospitals and the community. Health care costs associated with cross infection are estimated at US$18-30 billion yearly in the USA and UK combined. Australian costs are expected to be proportionate [3] . Furthermore, based on the existing SCI UTI prevention literature, we have demonstrated that current commonly used methods of non-antibiotic UTI prevention in SCI do not work [4] . The prevention of UTI, particularly the more difficult to treat MRO UTI, is therefore a clinical imperative for those people with SCI and neurogenic bladder. Non-antibiotic prevention is needed to prevent UTI without increasing the antimicrobial resistance burden [5] .
Probiotics are defined as a preparation containing viable, defined micro-organisms in sufficient numbers, which alter the microflora [by implantation or colonization] in a compartment of the host and thus exert beneficial health effects in this host [6] . Reid postulated that probiotics could reduce antibiotic related superinfections, disrupt bacterial biofilms, and enhance generalised mucosal immunity in the gastrointestinal and genitourinary systems [7] . In a systematic review conducted by Falagas et al., it was concluded that several probiotics tested, e.g. Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14, delivered either intravaginally or orally, were efficacious in restoring vaginal flora and in preventing recurrent UTIs in women [8] . In another trial, Manley et al. demonstrated clearance of vancomycinrelated enterococci in stool after treatment with Lactobacillus rhamnosus GG [9] .
There are currently no known trials of oral probiotics and its efficacy in prevention of UTIs in people with neurogenic bladders. Darouiche and others have conducted more invasive trials involving inoculating neurogenic bladders with benign strains of Escherichia coli and showed this approach was effective at lowering the rate of UTIs per year [10] [11] [12] .
Study aims Primary aim
To test the effectiveness of combination oral probiotic therapy Lactobacillus reuteri RC- 14 
Sample size
The trial uses a factorial design which allows the two probiotics to be compared with placebo simultaneously without inflating the sample size, on the assumption that they do not interact with each other. [Refer Table 1 ].
UTI prevention: In our previous RCT with the same study population [4] , 45 % of participants had a symptomatic UTI within six months. To have 80 % power to detect [at 5 % two-sided significance level] a 30 % reduction in the treatment group requires a total sample size of 350. Allowing for a 5 % loss to follow-up a final sample size of 372 is required, 93 participants being randomly allocated to each of the four study groups.
MRO treatment: It is expected that approximately 40 % participants will be MRO-positive at enrolment. Assuming 5-10 % become MRO-negative in the control group, a 15-20 % reduction in MRO-positive colonisation rate with probiotics would be detectable as significant at the 5 % level, with 80 % power, with a sample size of 372.
Randomisation and blinding of assessors
A simple stratified [computer generated] randomisation protocol is used. JS is responsible for generating the allocation sequence. Randomisation is stratified by bladder management types [indwelling/suprapubic vs intermittent catheters vs condom drainage/reflex voiding] as well as inpatient/outpatient status. Randomisation occurs following participant's compliance check at Day 4. One central pharmacy is responsible for the assignment and distribution of the intervention for the entire study. All four treatment regimens will be indistinguishable by appearance and taste, and all participants receive the same quantity of tablets. All clinical staff, researchers and participants remain blind to treatment allocation throughout this process. An audit of randomisation, product allocation and dispensing stock will be performed at the completion of the study by MT, who is not affiliated with the final analysis and the clinical management of the study or study participants.
Participants
All participants are to be over 18 years of age and are required to provide written consent. All participants with known neurogenic bladder as a result of SCI who meet inclusion criteria and gave written consent are enrolled. BL, ST, SR, JK, LB, GW and CBR are responsible for enrolling participants. Each participant is enrolled for a six month study period, which includes 24 weeks of treatment [see Fig. 1 ]. Each participant randomised is required to take two tablets orally each day consisting of either RC14-GR1 + LGG-BB12 Microbiological swabs of rectum, nose and groin, urine culture and collection of urinary catheters for participants with indwelling or suprapubic catheters -baseline, 3 months and 6 months. Urine cultures also performed if at study endpoint. Specific instructions for sampling were given by study co-ordinator to research assistants and community nurses performing the swabs to ensure consistency. Bowel questionnaire [13, 14] -baseline and 3 months.
Catheter-bioflora analysis
The indwelling urethral and suprapubic catheter biofilm is examined as a proxy for the urinary tract microbial community. Culture-independent techniques in profiling human microbes will be used to determine the composition of adherent microbes through the examination of the bacterial 16S rDNA gene by Terminal Restriction Fragment Length Polymorphism [TRFLP] [15] and via next-generation sequencing [16] [17] [18] [19] Samples are selected irrespective of interventional grouping.
Samples are also selected from groups with recurrent symptomatic UTI compared to no-UTI symptoms over the study follow-up period. All TRFLP and sequencing analysis will be conducted blinded by the use of a participant identification key that de-identifies the data.
TRFLP is done in collaboration with the Ramaciotti Centre for Genomics, University of New South Wales and sequencing through the Singapore Centre for Environmental Life Sciences Engineering at Nanyang Technological University, Singapore.
Study endpoints
1. The primary outcome measure is the time from randomisation to occurrence of "symptomatic UTI" [Fig. 2 ]. The date of the endpoint is the date participants develop symptoms consistent with a "symptomatic UTI" as per the algorithm, not the date participants start developing any symptoms. Table 2 outlines the definition of "symptomatic UTI" as primary endpoint for ProSCIUTTU. For participants who do not experience a "symptomatic UTI", the primary outcome is at six months. Participants who cease intervention early are followed up until the end of the study period. 
Data analysis
All analyses of outcomes will be by intention to treat, apart from safety outcomes which will be according to actual treatment received. Primary and MRO outcomes will be analysed using survival analysis. Cox regression modelling will be performed to test the effect of each treatment while allowing for the other, assuming no interaction effect. Hazard ratios and Kaplan-Meier survival curves will be used to summarise results. The extremely high prevalence of MRO in SCI will also allow us to explore whether probiotics can treat [or prevent] MRO colonisation in this group. A survey was sent out to selected co-authors for determining the strength of association of several variables in regards to UTI in the SCI population [pre hoc review]. Only variables which have strong or moderate association will be included in the analysis.
Biofilms will be analysed using a combination of RNA based meta-community sequencing, TRFLP fingerprinting and culture based methods.
Trial data management
The data will be collected on trial specific case record forms. OM is responsible for designing and maintaining the trial database. Following each study visit, a study team member will ensure data is complete. Databases will be commissioned within the SCI units and will contain non-identifiable data. Re-identifiable data will be available for use only by the study team. Primary outcome measure endpoint determination will be verified by BL and ST. The two assessors will be blinded by each other's assessment. Discrepancies will be decided by a third investigator [KC] .
Feasability, safety, efficacy Efficacy
The primary study endpoint is symptomatic UTI with microbiological evidence of infection [refer to Fig. 2 A cost-effectiveness analysis will be undertaken using SF-6D utility weights derived from the SF-36. In addition to antibiotic use, the following Table 2) resource data will also be collected during the study: 
Safety monitoring
An independent Safety Monitoring Committee [SMC] is established. Clinicians or investigators responsible for the clinical care of study participants were not permitted to be members of the SMC. The SMC will monitor the trial and review safety data by treatment allocation. Safety monitoring will be carried out at various intervals through the trial depending on frequency of adverse events. The Committee will review laboratory data, Grade 3, Grade 4 and Grade 5 adverse events and serious adverse events [SAEs] and adverse events leading to cessation of study therapy [refer Table 3 ]. A summary of safety data will be undertaken when all recruited participants have completed 20 weeks on study.
The SMC Chairman had no formal affiliation with the trial and coordinated this process.
Project governance and administration support
The chief investigator Dr. Bon San Bonne Lee will be responsible for overall project management, but is assisted and advised by a project steering committee comprised of the collaborating researchers and administrative support from the administering institution [NeuRA] . The project steering committee will meet regularly and all agendas and minutes circulated to all stakeholders. Table 2 Definition of "symptomatic UTI" as primary endpoint for ProSCIUTTU (need to refer to Fig. 2) . Use the following table to assess "Category 1", or Two "Category 2" and any "Category 3" Symptoms: All symptoms should be asked in each category "Category 1" Symptoms:* "Category 2" Symptoms:* "Category 3" Symptoms:
Two or more In themselves not enough to lead to treatment but recorded for International Spinal Cord Injury Urinary Tract Infection Datasets Compatibility
• Temperature:Greater than 38°C core Greater than 37.5°C per axilla • New or increasing symptoms of Autonomic Dysreflexia, as detected by any of the following signs: Pulse < 50 or increased flushing or sweating or headache AND increased B.P Diastolic or Systolic > 25 % usual baseline.
• Grade 3 clinically significant laboratory abnormalities should be confirmed by repeat testing within three to five calendar days of receipt of results and before discontinuation, unless such a delay is not consistent with good medical practice For grade 3 clinical events, continue if the event is considered to be unrelated to the intervention. For a grade 3 clinical event, or clinically significant laboratory abnormality confirmed by repeat testing, that is considered to be related to the intervention, both oral and bodywash interventions should be withheld until the toxicity returns to ≤ grade 2. When restarting following resolution of the adverse event, both interventions to be restarted simultaneously following discussion with the study monitor Grade 4 Laboratory Abnormality or Clinical Event For grade 4 clinical event or clinically significant laboratory abnormality confirmed by repeat testing that is considered related to the intervention, the intervention should be permanently discontinued and subjects managed according to local practice. The subject should be followed as clinically indicated until the event resolves to baseline, or is otherwise explained, whichever occurs first. Study interventions may be continued without modification for non-clinically significant grade 4 laboratory abnormality (e.g. triglyceride elevation that is non-fasting or that can be medically managed) or clinical event considered unrelated to the study intervention Competing interests CHR Hansen has been paid commercial rates for providing the intervention product and placebo. The company had no input into the design of the trial. BL, JS, SG and JM have received competitive research funding support from the National Health and Medical Research Council of Australia [NHMRC] . They declare that they have no other financial or non-financial competing interests. The rest of the authors have no competing financial or non-financial interests.
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